Zhewitra contains the active ingredient vardenafil, which belongs to a class of medications known as phosphodiesterase type 5 (PDE5) inhibitors. The mechanism of action of Zhewitra involves its ability to inhibit the enzyme phosphodiesterase type 5.
Here's how it works:
Erection Process: During sexual arousal, nitric oxide (NO) is released in the erectile tissue of the penis. Nitric oxide stimulates the production of cyclic guanosine monophosphate (cGMP), which causes relaxation of the smooth muscles in the penile arteries and corpus cavernosum (erectile tissue). This relaxation allows increased blood flow into the penis, resulting in an erection.
Role of PDE5: Phosphodiesterase type 5 (PDE5) is an enzyme that breaks down cGMP, leading to the termination of the erection process. In individuals with erectile dysfunction, there is often an overactivity of PDE5, resulting in insufficient cGMP levels and impaired erectile function.
Inhibition of PDE5: Vardenafil, the active ingredient in Zhewitra, selectively inhibits the action of PDE5. By blocking PDE5, vardenafil helps to preserve the levels of cGMP in the erectile tissue, prolonging its effects. This allows for enhanced relaxation of the smooth muscles and increased blood flow to the penis, facilitating the achievement and maintenance of an erection.
Enhanced Erectile Response: With inhibition of PDE5 by vardenafil, there is improved erectile response to sexual stimulation. The increased blood flow to the penis results in firmer and longer-lasting erections, improving overall sexual satisfaction and performance.
It's important to note that sexual stimulation is still required for Zhewitra to be effective. Vardenafil does not directly cause an erection but enhances the body's natural response to sexual stimulation by improving blood flow to the penis. Additionally, Zhewitra should be taken as directed by a healthcare provider, and its use should be accompanied by appropriate sexual arousal for optimal results.